Document:

Exhibit 10.2

     

    EXHIBIT
      10.2

     

    

    

    

    September
      19, 2006

    

    

    Re:
      Collaboration and License Agreement dated as of August 1, 2006 by and between
      POZEN INC. and Astrazeneca AB (the "Collaboration Agreement")

    

    

    Dear
      Denise:

    

    This
      letter sets forth the understanding between POZEN INC. (“POZEN”) and Astrazeneca
      AB (“Astrazeneca”) with regard to the matters set forth below and in connection
      with the Collaboration Agreement. Any capitalized terms not otherwise defined
      herein shall have the meaning given such term in the Collaboration Agreement.
      POZEN and Astrazeneca herein are collectively referred to as the Parties.

    

    1. In
      accordance with Section 12.1 of the Collaboration Agreement, the Effective
      Date
      of the Collaboration Agreement is September 7, 2006.

    

    2. The
      Parties have attached hereto final versions of Schedule 10.1 and Schedule 10.7,
      which shall be incorporated by this reference and made part of the Collaboration
      Agreement.

    

    3. The
      Parties agree that a final schedule of Formulation Development Activities and
      a
      Formulation Budget pursuant to Section 6.1.4 of the Collaboration Agreement
      shall be agreed by the Parties as soon as reasonably practicable but not later
      than *****. 

    

    4. This
      letter is being executed pursuant to the terms of Section 15.6 of the
      Collaboration Agreement and shall be governed by the general terms of Article
      15
      of the Collaboration Agreement. Except as otherwise expressly provided in this
      letter, the terms of the Collaboration Agreement shall remain in full force
      and
      effect. This letter may be executed in counterparts, each of which when so
      executed and delivered shall be an original, and all of which together shall
      constitute one instrument. 

    

    

    
      
        *****
          Portion for which confidential treatment requested.

        
        

      

      
        
          

        

      

      
        
        

      

    

    If
      this
      letter reflects your understanding, please countersign in the space provided
      below and return one original copy to POZEN by facsimile at (919) 913-1039.
      

    

    

    Regards,
      

    

    ________________________

    John
      R.
      Plachetka

    Chairman,
      President and CEO

    

    

    

    AGREED:

    

    ASTRAZENECA
      AB (publ)

    

    
      	
              By:

            	 
	
              Name:

            	
              Denise
                Goode

            
	
              Title:

            	
              Licensing
                Director

            

    

    

    

    

    
      
        
          *****
            Portion for which confidential treatment requested.

        

        
        

      

      
        -
          2
          -

        
          

        

      

      
        
        

        
        

      

    

    

    

    SCHEDULE
      10.1 

    

    

    Part
      10.1.14 - Agreements

    

    
      	
              Consultant/Vendor

            	
              Form
                of Contract

            	
              Service
                Description

            
	 	 	 
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	 	 	 
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            
	
              *****

            	
              *****

            	
              *****

            

    

    

    

    

    

    

    

    

    

    

    
      
        *****
          Portion for which confidential treatment requested.

        
        

      

      
        -
          3
          -

        
          

        

      

      
        
        

      

    

    SCHEDULE
      10.7 

    POZEN
      SUBCONTRACTORS

    

    

    

    

    *****

    

    If
      AstraZeneca provides POZEN with written notice describing in reasonable detail
      information that has reasonably and in good faith caused AstraZeneca to believe
      that it would not be in the best interest of the Product for POZEN to enter
      into
      any new subcontract with any of the subcontractors listed above, then POZEN
      will
      not, without AstraZeneca’s prior written consent (not to be unreasonably
      withheld) engage such subcontractor in the conduct of Development activities
      under the Agreement. 

    

    

    

    

    

    301264
      v2/RE 

    
      
        *****
          Portion for which confidential treatment requested.

        
        

      

      
        -
          4
          -Filed by Automated Filing Services Inc. (604) 609-0244 - Nuport Group, Inc. - Exhibit 10.1

ASSET PURCHASE AGREEMENT 

THIS AGREEMENT dated the 29th day of JANUARY,
2006. 

BETWEEN: 

JAMES LAIRD 

(the “Vendor”)

OF THE FIRST PART 

AND: 

NUPORT GROUP

(the “Purchaser”)

OF THE SECOND PART

WHEREAS:

A.        The Vendor is the
registered and beneficial owner of various mineral claims (hereinafter the
“Claims”), collectively called CONSTITUTION GOLD PROPERTY. The Claims of
the Vendor are more particularly described in Schedule “A” attached hereto and
forming part of this Agreement;

B.        The Vendor has
agreed to sell and the Purchaser has agreed to purchase all of the Claims of the
Vendor in accordance with the terms of this Agreement.

NOW THEREFORE THIS AGREEMENT WITNESSES that in
consideration of the terms and covenants herein and other good and valuable
consideration, the receipt and sufficiency of which each party acknowledges, the
parties hereto agree as follows:

1.        PURCHASE AND
SALE OF ASSETS

1.1     Sale of Assets. Subject to
the terms and conditions of this Agreement, the Vendor hereby sells, assigns and
transfers to the Purchaser, and the Purchaser hereby purchases the Vendor’s
Claims.

	1.2 	
      Purchase Price. The purchase price payable by the
      Purchaser to the Vendor for the Vendor’s Claims is USD $ 6000 (the
      “Purchase Price”). If applicable, subject to a carried 3% Net
      Smelter Royalty as described in Appendix “A”.

	1.3 	
      Payment of the Purchase Price. The Purchase Price
      will be paid by the delivery of a cheque.

1.4     Delivery of Claims. The
Vendor delivers to the Purchaser, on execution hereof, all of the Claims
unconditionally and free and clear of all liens, charges, or encumbrances,
except where disclosed.

2.       
COVENANTS OF THE PARTIES

2.1     Covenants. The parties
undertake to keep the information with respect to this Agreement, the terms
herein, and any related, underlying or subsequent agreements (the
“Information”) confidential and not to directly or indirectly disclose
the Information at any time to any person or persons or use the Information for
any purpose whatsoever.

3.       
REPRESENTATIONS OF THE VENDOR

3.1     Representations. The Vendor
represents and warrants to the Purchaser as follows, with the intent that the
Purchaser will rely on the representations in entering into this Agreement, and
in concluding the purchase and sale contemplated by this Agreement:

	 	(a) 	
      Capacity to Sell. The Vendor is James Laird,
      having the power and capacity to own and dispose of the Claims, and to
      enter into this Agreement and carry out its terms to the full
    extent;

	 	 	 	 
	 	(b) 	
      Authority to Sell. The execution and delivery of
      this Agreement, and the completion of the transaction contemplated by this
      Agreement has been duly and validly authorized by all necessary corporate
      action on the part of the Vendor, and this Agreement constitutes a legal,
      valid and binding obligation of the Vendor enforceable against the Vendor
      in accordance with its terms except as may be limited by laws of general
      application affecting the rights of creditors;

	 	 	 	 
	 	(c) 	
      Sale Will Not Cause Default. Neither the execution
      and delivery of this Agreement, nor the completion of the purchase and
      sale contemplated by this Agreement will:

	 	 	 	 
	 		(i) 	
      violate any of the terms and provisions of the constating
      documents or bylaws or articles of the Vendor, or any order, decree,
      statute, bylaw, regulation, covenant, restriction applicable to the Vendor
      or the Claims;

	 	 	 	 
	 		(ii) 	
      give any person the right to terminate, cancel or
      otherwise deal with the Claims; or

	 		(iii) 	
      result in any fees, duties, taxes, assessments or other
      amounts relating to the Claims becoming due or payable other than tax
      payable by the Purchaser in connection with the purchase and
  sale;

	 	 	 	 
	 	(d) 	
      Encumbrances. The Vendor owns and possesses and
      has a good marketable title to the Claims free and clear of all legal
      claims, mortgages, liens, charges, pledges, security interest,
      encumbrances or other claims, except where as disclosed;

	 	 	 	 
	 	(e) 	
      Litigation. There is no litigation or
      administrative or governmental proceeding or inquiry pending or, to the
      knowledge of the Vendor, threatened against or relating to the Claims, nor
      does the Vendor know of or have reasonable grounds that there is any basis
      for any such action, proceeding or inquiry;

	 	 	 	 
	 	(f) 	
      No Defaults. Except as otherwise expressly
      disclosed in this Agreement there has not been any default in any
      obligation to be performed under any of the Claims, which are in good
      standing and in full force and appropriate effect; and

	 	 	 	 
	 	(g) 	
      Good Standing. Prior to closing this Agreement,
      the Vendor will maintain, as required, the Claims in good
  standing.

4.       
COVENANTS OF THE VENDOR

4.1      Procure Consents. The
Vendor will diligently and expeditiously take all reasonable steps requested by
the Purchaser to obtain all necessary consents to effect the transfer of the
Claims.

4.2     Covenant of Indemnity. The
Vendor will indemnify and hold harmless the Purchaser from and against:

	 	(a) 	
      any and all liabilities, whether accrued, absolute,
      contingent or otherwise, existing at closing and which are not agreed to
      be assumed by the Purchaser under this Agreement;

	 	 	 
	 	(b) 	
      any and all losses, claims, damages and costs incurred or
      suffered by the Purchaser arising out of the breach or inaccuracy of any
      representation or warranty of the Vendor contained in this Agreement;
      and

	 	 	 
	 	(c) 	
      any and all actions, suits, proceedings, demands,
      assessments, judgments, costs and legal and other expenses incident to any
      of the foregoing.

	4.3 	
      Execution of all necessary documents. The Vendor
      will execute all necessary documents including such assignments as the
      Purchaser may require to effect the transfer of all of the Claims,
      including but not limited to, internet contracts and internet
  names.

	 	 
	5. 	
      REPRESENTATIONS OF THE
  PURCHASER

5.1     Representations. The
Purchaser represents and warrants to the Vendor as follows, with the intent that
the Vendor will rely on these representations and warranties in entering into
this Agreement, and in concluding the purchase and sale contemplated by this
Agreement:

	 	(a) 	
      Status of Purchaser. The Purchaser is a
      corporation duly incorporated, validly existing and in good standing and
      has the power and capacity to enter into this Agreement and carry out its
      terms; and

	 	 	 
	 	(b) 	
      Authority to Purchase. The execution and delivery
      of this Agreement and the completion of the transaction contemplated by
      this Agreement has been duly and validly authorized by all necessary
      corporate action on the part of the Purchaser, and this Agreement
      constitutes a legal, valid and binding obligation of the Purchaser
      enforceable against the Purchaser in accordance with its terms except as
      limited by laws of general application affecting the rights of
      creditors.

	6. 	
      COVENANTS OF THE PURCHASER

	 	 
	6.1 	
      Consents. The Purchaser will at the request of the
      Vendor execute and deliver such applications for consent and such
      assumption agreements, and provide such information as may be necessary to
      obtain the consents referred to in paragraph 4.1 and will assist and
      cooperate with the Vendor in obtaining the consents.

	 	 
	6.2 	
      Execution of all necessary documents. The
      Purchaser will execute all necessary documents as the Vendor may require
      to effect the transfer of all of the Claims.

	 	 
	7. 	
      SURVIVAL OF REPRESENTATIONS AND
      COVENANTS

7.1     Vendor's Representations and
Covenants. All representations, covenants and agreements made by the Vendor
in this Agreement or under this Agreement will, unless otherwise expressly
stated, survive closing and any investigation at any time made by or on behalf
of the Purchaser will continue in full force and effect for the benefit of the
Purchaser.

7.2     Purchaser’s Representations and
Covenants. All representations, covenants and agreements made by the
Purchaser in this Agreement or under this Agreement will, unless otherwise
expressly stated, survive closing and any investigation at any time made 

by or on behalf of the Vendor and will continue in full force
and effect for the benefit of the Vendor.

8.       
LIABILITIES NOT ASSUMED

8.1     Liabilities Not Assumed. The
Purchaser will not assume any liabilities of the Vendor. The Purchaser will not
be responsible for any liability of the Vendor, past, present or future,
relating to the Claims, and the Vendor will indemnify and save harmless the
Purchaser from and against any such claim.

9.       
CONDITIONS PRECEDENT TO THE OBLIGATIONS OF THE
PURCHASER

9.1     Conditions. All obligations
of the Purchaser under this Agreement are subject to the fulfillment of the
following conditions:

	 	(a) 	
      Vendor's Representations. The Vendor’s
      representations contained in this Agreement will be true.

	 	 	 
	 	(b) 	
      Vendor’s Covenants. The Vendor will have performed
      and complied with all agreements, covenants and conditions as required by
      this Agreement.

	 	 	 
	 	(c) 	
      Consents. The Purchaser will have received duly
      executed copies of the consents or approvals referred to in paragraph
      4.1.

9.2     Exclusive Benefit. The
foregoing conditions are for the exclusive benefit of the Purchaser and any such
condition may be waived in whole or in part by the Purchaser delivering to the
Vendor a written waiver to that effect signed by the Purchaser.

10.     CONDITIONS PRECEDENT
TO THE OBLIGATIONS OF THE VENDOR

10.1    Conditions. All obligations of
the Vendor under this Agreement are subject to the fulfillment of the following
conditions:

	 	(a) 	
      Purchaser's Representations. The Purchaser’s
      representations contained in this Agreement will be true.

	 	 	 
	 	(b) 	
      Purchaser’s Covenants. The Purchaser will have
      performed and complied with all covenants, agreements and conditions as
      required by this Agreement.

	 	 	 
	 	(c) 	
      Consents of Third Parties. All consents or
      approvals required to be obtained by the Vendor for the purpose of
      selling, assigning or transferring the Claims have been obtained, provided
      that this condition may only be

relied upon by the Vendor if the Vendor has diligently
exercised its best efforts to procure all such consents or approvals and the
Purchaser has not waived the need for all such consents or approvals.

10.2    Exclusive Benefit. The foregoing
conditions are for the exclusive benefit of the Vendor and any such condition
may be waived in whole or in part by the Vendor delivering to the Purchaser a
written waiver to that effect signed by the Vendor.

	11. 	
      GENERAL

	 	 
	11.1 	
      Governing Law. This Agreement and each of the
      documents contemplated by or delivered under or in connection with this
      Agreement are governed exclusively by, and are to be enforced, construed
      and interpreted exclusively in accordance with the laws of British
      Columbia which will be deemed to be the proper law of the
  Agreement.

	 	 
	11.2 	
      Professional Fees. Each of the parties will bear
      the fees and disbursements of their respective lawyers, advisers and
      consultants engaged by them respectively in connection with the
      transactions contemplated by this Agreement prior to the
closing.

	 	 
	11.3 	
      Assignment. No party will assign this Agreement,
      or any part of this Agreement, without the prior written consent of the
      other party. Any purported assignment without the required consent is not
      binding or enforceable against any party.

	 	 
	11.4 	
      Enurement. This Agreement enures to the benefit of
      and binds the parties and their respective successors and permitted
      assigns.

	 	 
	11.5 	
      Notice. All notices required or permitted to be
      given under this Agreement will be in writing and personally delivered to
      the address of the intended recipient set out on the first page of this
      Agreement or at such other address as may from time to time be notified by
      any of the parties in the manner provided in this Agreement.

	 	 
	11.6 	
      Further Assurances. The parties will execute and
      deliver all further documents and take all further action reasonably
      necessary or appropriate to give effect to the provisions and intent of
      this Agreement and to complete the transactions contemplated by this
      Agreement.

	 	 
	11.7 	
      Remedies Cumulative. The rights and remedies under
      this Agreement are cumulative and are in addition to and not in
      substitution for any other rights and remedies available at law or in
      equity or otherwise. Any party to this Agreement may terminate this
      Agreement if any other party is in breach of or defaults under any
      material term or condition of this Agreement or has made a material
      misrepresentation in this Agreement. No single or partial exercise by a
      party of

		
      any right or remedy precludes or otherwise affects the
      exercise of any other right or remedy to which that party may be
      entitled.

	 	 
	11.8 	
      Entire Agreement. This Agreement constitutes the
      entire agreement between the parties and there are no representations,
      express or implied, statutory or otherwise and no collateral agreements
      other than as expressly set out or referred to in this
Agreement.

	 	 
	11.9 	
      Headings. The division of this Agreement into
      sections and the insertion of headings are for convenience only and do not
      form part of this Agreement and will not be used to interpret, define or
      limit the scope, extent or intent of this Agreement.

	 	 
	11.10 	
      Severability. Each provision of this Agreement is
      severable. If any provision of this Agreement is or becomes illegal,
      invalid or unenforceable, the illegality, invalidity or unenforceability
      of that provision will not affect the legality, validity or enforceability
      of the remaining provisions of this Agreement.

	 	 
	11.11 	
      Schedules. The Schedules attached hereto form an
      integral part of this Agreement.

	 	 
	11.12 	
      Time of the Essence. Time will be of the essence
      of this Agreement.

	 	 
	11.13 	
      Counterparts. This Agreement and all documents
      contemplated by or delivered in connection with this Agreement may be
      executed and delivered by facsimile or original and in any number of
      counterparts, and each executed counterpart will be considered to be an
      original. All executed counterparts taken together will constitute one
      agreement.

IN WITNESS WHEREOF the parties have duly executed this
Agreement by their duly authorized officers effective the first day and year
written above.

VENDOR: JAMES LAIRD

per: /s/ James Laird

PURCHASER: LORNE CHOMOS

By: /s/ Lorne Chomos

SCHEDULE “A”

THIS IS SCHEDULE “A” to the Asset
Purchase Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]